Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Deficit

v3.10.0.1
Stockholders' Deficit
6 Months Ended
Jun. 30, 2018
Equity [Abstract]  
Stockholders' Deficit

Note 13 – Stockholders’ Deficit

 

Preferred Stock

 

The Company has 5,000,000 shares, par value $0.01, of preferred stock authorized. As of June 30, 2018, the Company had outstanding shares of preferred stock consisting of shares of its Series I-1 Preferred Stock and shares of Series I-2 Preferred Stock (both of which are more fully discussed in Note 12), 215 shares of its Series G Preferred Stock, 10 shares of its Series H Preferred Stock and 1,750,000 shares of its Series F Convertible Preferred Stock. During the three months ended June 30, 2018, 50 shares of the Series H Preferred Stock were converted into 20,000,000 shares of the Company’s common stock.

 

The rights of Preferred F, G, and H are disclosed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017. The Series G and H preferred stock are convertible into shares of the Company’s common stock at a price equal to 85% of the volume weighted average price of the Company’s common stock at the time of conversion. The Series F Preferred Stock is convertible into shares of the Company’s common stock at a fixed price of $29.25 per share.

 

Common Stock

 

On May 9, 2018, the Company held a Special Meeting of Stockholders, in part, to approve an amendment to the Company’s Certificate of Incorporation, as amended, to increase the number of authorized shares of common stock from 500,000,000 to 3,000,000,000 shares. The proposal was approved and on May 9, 2018 the Company filed an amendment to its Certificate of Incorporation to increase its authorized common stock to 3,000,000,000 shares.

 

The Company had 1,591,673,800 and 19,750,844 shares of common stock issued and outstanding at June 30, 2018 and December 31, 2017, respectively. During the six months ended June 30, 2018, the Company:

 

  issued an aggregate of 1,118,810,452 shares of its common stock upon conversion of $5.8 million of the principal amount of the March 2017 Debentures. The value of the common stock issued was based on the fair value of the stock at the time of issuance;
     
  issued 361,840,000 shares of common stock upon exercise of 550,652,213 warrants, on a cashless basis; and
     
  issued 20,000,000 shares of common stock upon the conversion of 50 shares of its Series H Preferred stock as discussed above.

 

Restricted Stock

 

On August 14, 2017, the Board of Directors, based on the recommendation of the Compensation Committee of the Board and in accordance with the provisions of the 2007 Equity Plan, approved grants to employees and directors of the Company of an aggregate of 181,933 shares of restricted common stock of the Company. The grants fully vest on the first anniversary of the date of grant, subject to the grantee’s continued status as an employee or director on the vesting date.

 

During the six months ended June 30, 2018:

 

  60,827 shares of the restricted stock were forfeited by their terms and returned to treasury.
     
  the Company issued an aggregate of 71,333,333 shares of restricted stock to employees and directors, based upon the recommendation of the Compensation Committee of the Board. The grants fully vested immediately. The Company recognized stock-based compensation in the amount of $477,933 for the grant of such restricted stock based on a valuation of $.0067 per share. In addition, the Company recorded $134,960 of compensation expense related to restricted stock issued in 2017. The value of the common stock issued was based on the fair value of the stock at the time of issuance.

 

Stock Options

 

During the six months ended June 30, 2018 and 2017, the Company recorded approximately $48,393 and $69,230, respectively, as stock compensation expense from the amortization of stock options issued in prior periods. As of June 30, 2018, the weighted average remaining contractual life was 8.0 years for options outstanding and exercisable. The intrinsic value of options exercisable at June 30, 2018 and 2017 was $0. As of June 30, 2018, the remaining expense is approximately $82,993 over the remaining amortization period which is 0.79 years under the Company’s 2007 Equity Plan. The Company estimates forfeiture and volatility using historical information. The risk-free interest rate is based on the implied yield available on U.S. Treasury zero-coupon issues over the equivalent lives of the options. The expected life of the options represents the estimated period using the simplified method. The Company has not paid cash dividends on its common stock and no assumption of dividend payment(s) is made in the model.

 

The following table summarizes the Company’s stock option activity for the six months ended June 30, 2018:

 

    Number of options     Weighted-average exercise price     Weighted-average contractual term (Yrs.)  
Outstanding at December 31, 2017     38,478     $ 2,072.75       8.33  
Granted     -       -          
Expired     -       -          
Forfeit           -          
Exercised     -       -          
Outstanding at June 30, 2018     38,478     $ 2,072.75       7.73  
Exercisable at June 30, 2018     32,922     $ 2,373.16          

 

Warrants

 

The Company, as part of various debt and equity financing transactions, has issued warrants to purchase shares of the Company’s common stock. The following summarizes the information related to warrants issued and the activity during the six months ended June 30, 2018:

 

    Number of
warrants
    Weighted average
exercise price
 
Balance at December 31, 2017     2,176,403,218     $ 0.0444  
Warrants issued during the period     -     $ -  
Increases due to dilution     30,081,680,059     $ -  
Warrants exercised during the period     (550,652,213 )   $ 0.0038  
Warrants expired during the period     -     $ -  
Balance at June 30, 2018     31,707,431,064     $ 0.0030  

 

Common Stock and Common Stock Equivalents

 

The Company has outstanding options, warrants, convertible preferred stock and convertible debentures. Exercise of the options and warrants, and conversions of the convertible preferred stock and debentures could result in substantial dilution of our common stock and a decline in its market price. In addition, the terms of certain of the warrants, convertible preferred stock and convertible debentures issued by us provide for reductions in the per share exercise prices of the warrants and the per share conversion prices of the debentures and preferred stock (if applicable and subject to a floor in certain cases), in the event that we issue common stock or common stock equivalents (as that term is defined in the agreements) at an effective exercise/conversion price that is less than the then exercise/conversion prices of the outstanding warrants, preferred stock and debentures. These provisions, as well as the issuances of debentures and preferred stock with conversion prices that vary based upon the price of our common stock on the date of conversion, have resulted in significant dilution of our common stock and have given rise to reverse splits of our common stock.

 

The following table presents the dilutive effect of our various potential common shares as of August 1, 2018:

 

    August 1, 2018  
Common shares outstanding     3,000,000,000  
Dilutive potential shares:        
Stock options     38,478  
Warrants     81,566,002,020  
Convertible debt     3,205,778,378  
Convertible preferred stock     13,063,630,114  
Total dilutive potential common shares, including outstanding common stock     100,835,448,990  

 

As of August 1, 2018, the Company lacked a sufficient number of authorized shares of its common stock to cover all potentially dilutive common shares outstanding.